Program
adebrelimab
Also written as “SHR-1316”, “Adebrelimab” and “Adebrelimab Injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Pancreatic Neoplasms · Neoplasms · Breast Neoplasms, led by 2 companies.
Drug pageAdebrelimab: every studyAll 205 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 4938 open or running | phase 3since Oct 16, 2018 | Apr 8, 2017 | Dec 2026phase 2 · NCT05482568 |
| Hansoh Pharmaceutical Group | 22 open or running | phase 2since Aug 13, 2026 | Jul 3, 2025 | Mar 30, 2028phase 2 · NCT07824882 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named adebrelimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, SHR-1316
- Jul 3, 2025First study: phase 1 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)First studyNCT07063407 · 50 planned
- Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07824882 · 76 planned · China
Ahead
- Mar 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07824882
TargetBeta
“An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 2 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07824882Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Mar 30, 2028 | 76 |
| NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 1 | Not yet recruiting | Apr 30, 2026 | 50 |
How it is read
Names in the registry
- “SHR-1316”, 8 entries
- “Adebrelimab”, 6 entries
- “Adebrelimab Injection”, 4 entries
- “adebrelimab + SHR-A2009”, 3 entries
- “HRS-717 + HRS-4642+SHR-1316;”, 3 entries
Codes read as this program: SHR1316.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Small Cell Lung Carcinoma, 6 studies
- Pancreatic Neoplasms, 3 studies
- Neoplasms, 3 studies
- Breast Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.